key: cord-1024299-d3mtgzer
authors: Eibschutz, Liesl S.; Rabiee, Behnam; Asadollahi, Shadi; Gupta, Amit; Assadi, Majid; Alavi, Abass; Gholamrezanezhad, Ali
title: FDG-PET/CT of COVID-19 and Other Lung Infections
date: 2021-06-22
journal: Semin Nucl Med
DOI: 10.1053/j.semnuclmed.2021.06.017
sha: f5ad7688e515158718d56ed17b62d39f67d54891
doc_id: 1024299
cord_uid: d3mtgzer

While not conventionally used as the first-line modality, [(18)F]-2-fluoro-2-deoxy-D-glucose (FDG) - positron emission tomography/computed tomography (PET/CT) can identify infection and inflammation both earlier and with higher sensitivity than anatomic imaging modalities [including chest X-ray (CXR), computed tomography (CT), and magnetic resonance imaging (MRI)]. The extent of inflammation and, conversely, recovery within the lungs, can be roughly quantified on FDG-PET/CT using maximum standardized uptake value (SUVmax) values. The Coronavirus disease 2019 (COVID-19) pandemic has highlighted the value of FDG-PET/CT in diagnosis, elucidation of acute pulmonary and extra-pulmonary manifestations, and long-term follow up. Similarly, many other pulmonary infections such as previously documented coronaviruses, Aspergillosis, Blastomycosis, Candidiasis, Coccidioidomycosis, Cryptococcosis, Histoplasmosis, Mucormycosis, and typical/atypical Mycobacterial infections have all been identified and characterized using FDG-PET/CT imaging. The goal of this review is to summarize the actual and potential benefits of FDG-PET/CT in the imaging of COVID-19 and other lung infections. Further research is necessary to determine the best indications and clinical applications of FDG-PET/CT, improve its specificity, and ultimately ascertain how this modality can best be utilized in the diagnostic work up of infectious pathologies.

For decades, acute lower respiratory tract infections have been one of the three leading causes of mortality in both adult and pediatric populations, creating a substantial burden on the healthcare system. While standard radiologic imaging techniques, mainly chest X ray (CXR) and CT, are the primary imaging modalities to diagnose lung infection, FDG-PET/CT has proven to be effective in cases where conventional imaging falls short. Not only can metabolic imaging identify and track the infection earlier than other methodologies, but it can also provide vital information at the molecular level 1, 2 . The high sensitivity of this modality coupled with wider anatomic coverage generates a more comprehensive and complete assessment of the patient's global disease burden, allowing for personalization of treatment strategy.

While the FDG-PET/CT imaging modality has primarily been reserved for imaging of malignancies, many authors have also recognized its value in non-neoplastic processes such as pulmonary infections. This is due to the fact that FDG acts as a glucose analogue, and thus gets taken up by the cell via glucose transporter 1(GLUT-1) 2 . After cellular uptake, FDG is phosphorylated by the rate-limiting enzyme hexokinase, trapping FDG-6-phosphate in the cell 2 .

This mechanism allows FDG-PET/CT to identify sites with increased glucose utilization and metabolism, which are non-specific but common markers of infection, inflammation, and malignancies.

Ultimately, combining the functional aspects of FDG-PET/CT with the structural/anatomic facets of CT has the potential to revolutionize the diagnosis and treatment of pulmonary infections. While not normally utilized as a stand-alone methodology in infectious/inflammatory processes, FDG-PET/CT imaging has great utility when used in conjunction with other imaging techniques, as it provides additional information on the molecular level and can accurately quantify disease burden. This review aims to highlight the value of nuclear imaging in elucidating a variety of lung infections.

The introduction of PET/CT using FDG opens new areas of research in diagnosis of inflammatory and infectious diseases. FDG is a nonspecific tracer, and its level of uptake is proportional to the cellular metabolic rate and the density of glucose transporters, thus FDG accumulates at sites of infection and inflammation 2, 3, 4, 5 . It is well established that inflammatory response, focal hyperemia, and increased vascular permeability are correlated with high uptake of FDG, with enhanced tissue blood perfusion leading to greater FDG delivery to the lesion site and local immune response resulting in release of pro-inflammatory cytokines and migration of inflammatory cells 6, 7 . As activated inflammatory cells such as neutrophils, macrophages, lymphocytes, and fibroblasts significantly take up FDG, there is a direct correlation between the FDG uptake and the quantity of inflammatory cells in both acute and chronic inflammation where expression of active glucose transporters is upregulated 8,9 . FDG avidity has been reported in the development of various pulmonary inflammatory and infectious diseases. In acute infection, FDG is absorbed mainly by activated parenchymal neutrophils, which are highly dependent on anaerobic glycolysis and demand high uptake of glucose. Therefore, FDG accumulates in the interstitial lung tissue and alveolar airspaces, permitting study of the behavior of inflammatory cells in their local microenvironment 4, 10 .

Over the past year, the global COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has affected over 170 million people worldwide, resulting in millions of patients developing pulmonary symptoms serious enough to require hospitalization and serial imaging. While reverse transcription-polymerase chain reaction (RT-PCR) CXR, and less commonly chest CT have been the primary tools of diagnosis, FDG-PET/CT may incidentally detect undiagnosed cases of COVID-19 in the early stages of infection, when symptoms are non-specific. Recent studies have reported incidental FDG-PET/CT findings confirming COVID-19 in asymptomatic patients, including one series of 7 patients with 2 consecutive negative RT-PCR tests 11 . The authors found that the pulmonary lesions displayed significantly increased SUVmax (mean ± standard deviation, 3.44 ± 2.03 vs 0.54 ± 0.19) when compared to the lungs of control subjects 11 . In another study, FDG-PET/CT showed new lung infiltrates in asymptomatic patients roughly 7 days (range of 6.4 +/-7.8 days) prior to symptom onset 12 . Therefore, routine staging FDG-PET/CT scans may show incidental but typical imaging findings of COVID -19 and help initiate further workup ( Figure 1 ). COVID-19 pneumonia is FDG avid, and numerous studies have documented lung uptake in both asymptomatic and symptomatic patients. As is typical on diagnostic CT, on FDG-PET/CT, ground glass opacifications (GGOs) with or without superimposed consolidation are appreciated in a peripheral, basilar, and posterior predominant pattern with increased metabolic activity 13 .

Less intense uptake may be seen in lymph nodes and bone marrow 14 

COVID-19 is known to be associated with extra-pulmonary involvement, such as renal dysfunction, hepatic, vascular, and myocardial injury, as well as neuromuscular and gastrointestinal abnormalities. Arterial and venous thrombosis have also been reported in 

The most common causes of respiratory infection are viral pathogens, including influenza virus, human parainfluenza virus, rhinovirus, respiratory syncytial virus, and adenovirus. On top of that, there have been several regional and global outbreaks of novel respiratory viral infections during the past decades, including severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), H1N1 and H5N1 influenza, and most recently, COVID-19. CXR and CT are the routinely utilized imaging modalities to investigate pulmonary changes at presentation, as well as to monitor disease progression and response to treatment. The most common CT findings in viral respiratory illnesses include diffuse ill-defined GGOs, consolidation, and interlobular septal thickening 45 . These findings however are highly nonspecific and can also be seen in some inflammatory diseases, as well as some non-viral infections 46 .

Acute inflammatory response has been shown to play an important role in the pathogenesis of severe respiratory dysfunction in respiratory viral infections such as H1N1, H5N1, and SARS 47, 48 . During the acute inflammatory phase of infection, activated neutrophils heavily utilize anaerobic glycolysis, which leads to increased FDG uptake 49 . Hence, FDG-PET/CT has the potential to assess the degree of inflammatory response in respiratory viral infections 47 . This uptake can be quantified and may be very helpful in delineating the extent of inflammation in lung tissue. Furthermore, it has been shown that increased FDG uptake is present not only in non-aerated portions of the lungs on CT scan, but also areas with preserved aeration. This suggests improved sensitivity and more accurate estimation of inflammation utilizing FDG-PET/CT 48 . Tracking the underlying inflammation could potentially be useful in monitoring disease progression, response to treatment, and confirming resolution of infection.

Taking advantage of the quantifiable FDG uptake during the inflammatory response to infections, PET/CT has the potential to be utilized for initial diagnosis, staging of invasive fungal infections, disease progression, and response to treatment 50, 51, 52 . Semi-quantitative FDG uptake has already been shown to be more accurate in measuring disease activity compared to morphological changes in lesion size visible on anatomic imaging 53 

Showing prominent FDG-avidity, pulmonary aspergillosis looks very similar to pulmonary malignancy on FDG-PET/CT, potentially creating confusion for the reading radiologist 51,55 .

However, FDG-PET/CT can be effective in differentiating invasive and non-invasive pulmonary aspergillosis, given the higher peak SUV in the former 14 . Imaging manifestations of invasive aspergillosis are defined as multiple hypermetabolic nodules, while in non-invasive aspergillosis, solitary metabolic nodules with halo pattern have been described 14 . FDG-PET/CT can also be utilized to investigate response to therapy in pulmonary aspergillosis, and has value in uncovering occult infection in the immunocompromised patient 56 .

Pulmonary blastomycosis can also mimic primary and metastatic lung malignancy on FDG-PET/CT, mostly due to high uptake in a nodular pattern 57, 58 . Preclinical studies on animal models with blastomycosis showed FDG uptake levels higher than lymphoma 59 . A potential of FDG-PET/CT in pulmonary blastomycosis is the fact that it can show the true extent of active infection by discovering disease sites which are otherwise clinically occult 59 .

Candidiasis lesions show increased FDG avidity on nuclear imaging, thus this modality could be utilized in guiding anti-candida therapy 60 . In support of this, Xu et al. performed a preliminary study in patients with chronic disseminated candidiasis, and noted that FDG-PET/CT provided utility in antifungal therapy response 53 . FDG-PET/CT can also help in the detection of occult sites of candidiasis in immunocompromised patients 50 .

Pulmonary coccidioidomycosis lesions have abnormal FDG uptake on PET/CT, but this modality is of limited use due to the difficulty differentiating these lesions from malignancy 61 .

Nonetheless, the median SUVmax is often more elevated in malignant lesions relative to coccidioidal nodules with SUVmax of greater than 5.9 suspicious for malignancy 62 . Nia et al.

reported a case of pulmonary coccidiomycosis with systemic involvement and discussed that FDG-PET/CT has the potential to guide medical management and help with investigating the extent of the disease, as well as response to therapy 63 .

Pulmonary cryptococcus involvement can show variable levels of FDG avidity in PET/CT, ranging from mild to pronounced uptake 64, 65 . The most common presentation is a solitary nodule, and less frequently: scattered nodular, clustered nodular, mass-like and bronchopneumonic patterns 66 . However, pulmonary cryptococcosis can show a similar pattern of FDG uptake to that of lung cancer 67, 68 . Thus, cryptococcosis should be kept in the differential diagnosis when evaluating lung malignancy with FDG-PET/CT, especially in endemic areas.

Thus far, multiple studies have indicated that FDG-PET/CT is unhelpful diagnostically, but may be useful when guiding response to treatment 51 

In a report, Dang et al. described their FDG-PET/CT findings in a case of pulmonary mucormycosis as prominent peripheral uptake in a heterogeneous soft tissue mass 74 . Recent studies have also begun to recognize increased rhino-orbital mucormycosis susceptibility in patients with moderate to severe COVID-19 infection 75 .

Tuberculosis (TB) infection of the lung primarily involves formation of a well-structured granuloma, in which immune cells and bacteria aggregate. In approximately 80% of cases, the lungs are the most common site of infection, but tuberculosis can disseminate to nearly any tissue or organ by hematogenous, lymphatic, or contiguous spread 49 .

FDG-PET/CT is a noninvasive tool capable of early detection and assessment of the disease involvement. This imaging modality is also capable of indicating enhanced glycolytic activity in both anaerobic and aerobic cells, thereby broadening its utility. This technique can demonstrate the disease extent, guide biopsy from active lesions, and find distant occult foci 76 . It can also measure treatment response to significantly optimize patient management.

As radio-labeled FDG accumulates in TB-related neutrophils, macrophages, and T-lymphocytes, (all present in active granulomatous foci), this imaging method has high precision in identifying active granulomatous sites 77, 78 While FDG-PET/CT has shown to be effective in assessing metabolic activity of pulmonary lesions, some studies have indicated that FDG-PET/CT is more efficient than CT in assessing extra-pulmonary involvement 86 

In addition to TB infection, nontuberculous mycobacterial (NTM) infections can be detected using FDG-PET/CT. NTM infections are caused by a diverse and emerging group of pathogens and are rapidly increasing worldwide 88 . Mycobacterium avium complex (MAC) is the most frequently isolated atypical mycobacterium found in these cases. Similar to TB, the lung is the most common site of involvement leading to nonspecific clinical signs which could remain underdiagnosed.

As FDG collects in granulation tissues formed by activation of macrophages in NTM infection, the amount of FDG accumulation is positively associated with the scope of active inflammatory areas 89 Another significant feature of FDG-PET/CT imaging is the potential capability in evaluating disease progression and follow-up in NTM patients. Namkoong et al. 92 , described an HIV and MAC-infected patient whose FDG-PET/CT findings identified disease progression on follow-up.

In addition, this imaging technique was useful for assessing the required duration of antimycobacterial therapy. Accordingly, FDG-PET/CT could play a valuable role in patient management, particularly in complicated cases such as HIV, in which TB and NTM infections often result in disseminated disease and tend to relapse even after treatments.

Pulmonary infectious diseases are a major cause of morbidity and mortality worldwide, thus the utilization of FDG-PET/CT in conjunction with conventional imaging techniques can yield early diagnosis and optimize treatment strategies. Throughout this paper, we have highlighted the added clinical value of FDG-PET/CT for diagnosis, elucidating acute pulmonary/extrapulmonary manifestations, and tracking treatment effectiveness. FDG-PET/CT imaging allows for a highly sensitive approach to imaging; thus, it has utility in recognizing disease early and guiding medical management. While usually not a first line imaging modality, FDG-PET/CT can be a useful adjunct to traditional imaging techniques to help reduce disease burden and provide vital information at the molecular level. In addition, FDG-PET/CT imaging is in alignment with medicine's shift to a more patient oriented approach 93 . Nuclear imaging has the advantage of allowing histological mapping and a personalized method of treatment, but further research is necessary to fully explore and validate the effectiveness of FDG-PET/CT imaging as a standalone modality in the setting of infectious diseases. 

Molecular imaging in pulmonary diseases

FDG PET/CT in infection and inflammation-current and emerging clinical applications

Current status of molecular imaging in infections

FDG PET of infection and inflammation

Diagnostic performance of 18F-FDG PET/CT in infectious and inflammatory diseases according to published meta-analyses

Evidence-Based PET for Infectious and Inflammatory Diseases

An update on the role of 18F-FDG-PET/CT in major infectious and inflammatory diseases

The impact of infection and inflammation in oncologic 18F-FDG PET/CT imaging

18F-FDG-PET/CT in Initiation and Progression of Inflammation and Infection

Advances in PET to assess pulmonary inflammation: A systematic review

Inflammatory response in lungs and extrapulmonary sites detected by [18 F] fluorodeoxyglucose PET/CT in convalescing COVID-19 patients tested negative for coronavirus

Asymptomatic SARS-CoV-2 infection-Incidental findings on FDG PET/CT

Portable chest X-ray in coronavirus disease-19 (COVID-19): A pictorial review

18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography findings are different between invasive and noninvasive pulmonary aspergillosis

18 F-FDG PET/CT findings of COVID-19: a series of four highly suspected cases

FDG PET/CT of COVID-19

COVID-19 pneumonia: relationship between inflammation assessed by whole-body FDG PET/CT and short-term clinical outcome

Long-term pulmonary consequences of coronavirus disease 2019 (COVID-19): what we know and what to expect

The lingering manifestations of COVID-19 during and after convalescence: update on long-term pulmonary consequences of coronavirus disease 2019 (COVID-19)

Chest-CT findings of COVID-19 in patients with pre-existing malignancies; a pictorial review

Registry of arterial and venous thromboembolic complications in patients with COVID-19

Potential role of FDG PET/CT imaging for assessing venous thromboembolic disorders

The role of molecular imaging in diagnosis of deep vein thrombosis

Venous thromboembolism detected by FDG

PET/CT in cancer patients: A life-threatening, yet commonly missed observation

Venous thromboembolism detected by FDG

PET/CT in cancer patients: a common, yet life-threatening observation

Extrapulmonary manifestations of COVID-19: Radiologic and clinical overview

COVID-19) outbreak: what the department of radiology should know

Neuroimaging findings in COVID-19 and other coronavirus infections: a systematic review in 116 patients

Neuroimaging findings in COVID-19: A narrative review

Ischemic gastrointestinal complications of COVID-19: a systematic review on imaging presentation

Middle East respiratory syndrome (MERS), influenza, and COVID-19, beyond the lungs: a review article

18FDG PET/CT scan reveals hypoactive orbitofrontal cortex in anosmia of COVID-19

18FDG-PET/CT Assessment of COVID-19-Induced Bell's Palsy

About the source and consequences of 18 F-FDG brain PET hypometabolism in short and long COVID-19

PET imaging as a tool for assessing COVID-19 brain changes

Vasculitis changes in COVID-19 survivors with persistent symptoms: an [18 F] FDG-PET/CT study

COVID-19 in the act: incidental 18F-FDG PET/CT findings in asymptomatic patients and those with symptoms not primarily correlated with COVID-19 during the United Kingdom coronavirus lockdown

Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19)

Available from

Reactive Axillary Lymphadenopathy to COVID-19 Vaccination on F18-FDG PET/CT

Oxford-AstraZeneca COVID-19 vaccination induced lymphadenopathy on [18F] choline PET/CT-not only an FDG finding

Covid-19 mRNA Vaccination: Age and Immune Status and its Association with Axillary Lymph Node PET/CT Uptake

Prevalence of Increased FDG PET/CT Axillary Lymph Node Uptake Beyond 6 Weeks after mRNA COVID-19 Vaccination

COVID-19 vaccine as a cause for unilateral lymphadenopathy detected by 18F-FDG PET/CT in a patient affected by melanoma

Axillary lymph node accumulation on FDG-PET/CT after influenza vaccination

Radiological findings in influenza and pneumonia

COVID-19 or non-COVID viral pneumonia: How to differentiate based on the radiologic findings?

Molecular imaging of influenza and other emerging respiratory viral infections

Imaging of lung inflammation during severe influenza A: H1N1

PET/CT in nononcological lung diseases: current applications and future perspectives

Diagnostic contribution of positron emission tomography with [18F] fluorodeoxyglucose for invasive fungal infections

Potential role of 18F-FDG PET/CT in patients with fungal infections

The Added Value of

PET/CT in the Management of Invasive Fungal Infections

Utility of FDG PET/CT in guiding antifungal therapy in acute leukemia patients with chronic disseminated candidiasis

FDG PET/CT imaging in detecting and guiding management of invasive fungal infections: a retrospective comparison to conventional CT imaging

Invasive aspergillosis mimicking metastatic lung cancer

Therapy monitoring in aspergillosis using F-18 FDG positron emission tomography

Pulmonary blastomycosis masquerading as metastatic disease in the lung: a case report

Pulmonary blastomycosis presenting as primary lung cancer

Characterization of uptake of 2-deoxy-2-[18F] fluoro-D-glucose by fungal-associated inflammation: the standardized uptake value is greater for lesions of blastomycosis than for lymphoma in dogs with naturally occurring disease

Hepatosplenic Candidiasis Imaged With F-18 FDG PET/CT

F-18 FDG PET/CT imaging of disseminated coccidioidomycosis

Positron emission tomography in the evaluation of pulmonary nodules among patients living in a coccidioidal endemic region

Tip of the Iceberg: 18F-FDG PET/CT Diagnoses Extensively Disseminated Coccidioidomycosis with

Pulmonary cryptococcosis in asymptomatic immunocompetent hosts

Characteristics of integrated 18F-FDG PET/CT in pulmonary cryptococcosis

18F-FDG PET/CT and contrast-enhanced CT findings of pulmonary cryptococcosis

Computed tomography (CT) and positron emission tomography with [18F] fluoro-2-deoxy-D-glucose (FDG-PET) images of pulmonary cryptococcosis mimicking lung cancer

Pulmonary cryptococcosis mimicking neoplasm in terms of uptake PET/CT

Thoracic Endemic Fungi in the United States: Importance of Patient Location

FDG-PET imaging and the diagnosis of non-small cell lung cancer in a region of high histoplasmosis prevalence

Dual time point positron emission tomography/computed tomography scan in evaluation of intrathoracic lesions in an area endemic for histoplasmosis and with high prevalence of sarcoidosis

The flip-flop fungus sign: an FDG PET/CT sign of benignity

18F-FDG PET/CT in initial staging and response assessment in patients with histoplasmosis

The appearance of pulmonary mucormycosis on FDG PET/CT

Rise of the phoenix: Mucormycosis in COVID-19 times

Pictorial essay: PET/CT in tuberculosis

Towards more accurate 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) imaging in active and latent tuberculosis

Comparison of 68Ga-DOTANOC with 18F-FDG using PET/MRI imaging in patients with pulmonary tuberculosis

18F-FDG PET/CT in the initial assessment and for follow-up in patients with tuberculosis

Advances in imaging of tuberculosis: the role of 18F-FDG PET and PET/CT. Current opinion in pulmonary medicine

Sterilization of granulomas is common in active and latent tuberculosis despite within-host variability in bacterial killing

Quantitative 18F-FDG PET-CT scan characteristics correlate with tuberculosis treatment response

PET/CT for monitoring the therapeutic response in a patient with abdominal lymph node tuberculosis after colon cancer resection

18F-FDG PET/CT in Tuberculosis: Can Interim PET/CT Predict the Clinical Outcome of the Patients?

18F-FDG PET/CT as a noninvasive biomarker for assessing adequacy of treatment and predicting relapse in patients treated for pulmonary tuberculosis

FDG-PET imaging in HIV infection and tuberculosis

18F-FDG PET-CT Diagnosis of Tuberculosis in Celiac Lymph Nodes

Characteristics of nontuberculous mycobacterial infections at a Midwestern Tertiary Hospital: A retrospective study of 365 patients

Analysis of pulmonary nodules caused by nontuberculous mycobacteriosis in 101 resected cases: multi-center retrospective study

Lung and nodal involvement in nontuberculous mycobacterial disease: PET/CT role

Usefulness of 18 F-fluorodeoxyglucose positron emission tomography for diagnosing disease activity and monitoring therapeutic response in patients with pulmonary mycobacteriosis

Immune reconstitution inflammatory syndrome due to Mycobacterium avium complex successfully followed up using 18 Ffluorodeoxyglucose positron emission tomography-computed tomography in a patient with human immunodeficiency virus infection: a case report

Future of nuclear medicine: SPECT versus PET

FDG PET of infection and inflammation